Company Overview
| Stock Name | Everest Med |
|---|---|
| Stock Code | 01952 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是一家生物製藥公司,業務包括潛在全球同類首創或同類最佳療法的許用、臨床開發及商業化,以解決大中華及亞太區其他新興市場尚未得到滿足的醫療需要。 |
| Listing Date | 2020-10-09 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市南京西路1266號上海恒隆廣場辦公樓1號樓6601–6606室 |
| Business Address (Hong Kong) | 香港皇后大道東183號合和中心54樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | everestmedicines.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 55.00 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 27,500 |
| Par Value | To be extracted |
| Offer Period | 2020-09-25 to 2020-09-30 |
| Global Offering Shares | 63,547,000 shares |
| HK Public Offer Shares (Initial) | 6,355,000 shares (10.0%) |
| Public Offer Lots (Initial) | 12,710lots (Pool A6,355lots,Pool B6,355lots) |
| International Placing Shares (Initial) | 57,192,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 283,690,389 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 49.9% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 3,495,085,000 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 27,500 |
| 2 lots | 1,000 | HK$ 55,000 |
| 3 lots | 1,500 | HK$ 82,500 |
| 4 lots | 2,000 | HK$ 110,000 |
| 5 lots | 2,500 | HK$ 137,500 |
| 6 lots | 3,000 | HK$ 165,000 |
| 7 lots | 3,500 | HK$ 192,500 |
| 8 lots | 4,000 | HK$ 220,000 |
| 9 lots | 4,500 | HK$ 247,500 |
| 10 lots | 5,000 | HK$ 275,000 |
| 12 lots | 6,000 | HK$ 330,000 |
| 14 lots | 7,000 | HK$ 385,000 |
| 16 lots | 8,000 | HK$ 440,000 |
| 18 lots | 9,000 | HK$ 495,000 |
| 20 lots | 10,000 | HK$ 550,000 |
| 30 lots | 15,000 | HK$ 825,000 |
| 40 lots | 20,000 | HK$ 1,100,000 |
| 50 lots | 25,000 | HK$ 1,375,000 |
| 60 lots | 30,000 | HK$ 1,650,000 |
| 70 lots | 35,000 | HK$ 1,925,000 |
| 80 lots | 40,000 | HK$ 2,200,000 |
| 90 lots | 45,000 | HK$ 2,475,000 |
| 100 lots | 50,000 | HK$ 2,750,000 |
| 120 lots | 60,000 | HK$ 3,300,000 |
| 140 lots | 70,000 | HK$ 3,850,000 |
| 160 lots | 80,000 | HK$ 4,400,000 |
| 180 lots | 90,000 | HK$ 4,950,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 200 lots | 100,000 | HK$ 5,500,000 |
| 300 lots | 150,000 | HK$ 8,250,000 |
| 400 lots | 200,000 | HK$ 11,000,000 |
| 500 lots | 250,000 | HK$ 13,750,000 |
| 600 lots | 300,000 | HK$ 16,500,000 |
| 700 lots | 350,000 | HK$ 19,250,000 |
| 800 lots | 400,000 | HK$ 22,000,000 |
| 900 lots | 450,000 | HK$ 24,750,000 |
| 1,000 lots | 500,000 | HK$ 27,500,000 |
| 1,200 lots | 600,000 | HK$ 33,000,000 |
| 1,400 lots | 700,000 | HK$ 38,500,000 |
| 1,600 lots | 800,000 | HK$ 44,000,000 |
| 1,800 lots | 900,000 | HK$ 49,500,000 |
| 2,000 lots | 1,000,000 | HK$ 55,000,000 |
| 3,000 lots | 1,500,000 | HK$ 82,500,000 |
| 4,000 lots | 2,000,000 | HK$ 110,000,000 |
| 5,000 lots | 2,500,000 | HK$ 137,500,000 |
| 6,355 lots | 3,177,500 | HK$ 174,762,500 |
Stock Connect Inclusion Analysis
| Avg Daily HK Mkt Cap | HK$ 11.05B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 15,602,971,395 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損人民幣176.1百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2018 | 2019-11 |
|---|---|---|
| Other income and gains, net | 0 | 514 |
| Administrative expenses | -15,417 | -107,756 |
| Operating profit | -22,096 | -131,132 |
| Net finance costs | 0 | -170,190 |
| Profit before tax | -22,096 | -301,322 |
| Income tax expense | 0 | 0 |
| Profit for the year | -22,096 | -301,322 |
Balance Sheet
| Item | 2018 | 2019-11 |
|---|---|---|
| Cash and cash equivalents | 34,281 | 98,442 |
| Total current assets | 34,281 | 199,468 |
| Total assets | 102,913 | 867,299 |
| Total current liabilities | 124,842 | 296,071 |
| Total liabilities | 124,842 | 1,193,917 |
| Total equity | -21,929 | -326,618 |
Cash Flow Statement
| Item | 2018 | 2019-11 |
|---|---|---|
| Net cash from operating activities | -202 | -168,875 |
| Net cash from investing activities | -69,156 | -655,498 |
| Net cash from financing activities | 103,734 | 884,757 |
| Net increase in cash | 34,281 | 64,161 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 72.75 |
|---|---|
| First Day Open | HK$ 70.55 |
| First Day Change | 32.27% |
| First Day Volume | 42603100.0 |
| First Day Turnover | 3078790000.0 |
| Use of Proceeds | 1、60%或約1,970.4百萬港元用于我們的四款支柱產品;
2、15%或約492.6百萬港元用于為我們管線中其他候選藥物的進行中及計劃臨床試驗、登記備案準備及潛在商業化提供資金;
3、15%或約492.6百萬港元用于為我們的業務發展活動及擴展藥品管線提供資金;
4、10%或約328.4百萬港元用作營運資金以及一般及行政用途。 |
Underwriting Syndicate
Joint Sponsors (2)
Overall Coordinators (5)
Joint Bookrunners (7)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
Merrill Lynch (Asia Pacific) Limited CE AAC198
Citigroup Global Markets Asia Limited CE AAA137
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Credit Suisse (Hong Kong) Limited CE AAO017
Nomura International (Hong Kong) Limited CE AAF742
Brocade River Asset Management Limited CE BNR589
Joint Lead Managers (7)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
Merrill Lynch (Asia Pacific) Limited CE AAC198
Citigroup Global Markets Asia Limited CE AAA137
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Credit Suisse (Hong Kong) Limited CE AAO017
Nomura International (Hong Kong) Limited CE AAF742
Brocade River Asset Management Limited CE BNR589
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | BlackRock Funds | 116,242,500 HKD | — | 3.33% | — | 6 months | 2021-04-09 |
| 2 | C-Bridge IV Investment Sixteen Limited | 232,485,000 HKD | — | 6.65% | — | 6 months | 2021-04-09 |
| 3 | Citadel Multi-Strategy Equities Master Fund Ltd. | 38,747,500 HKD | — | 1.11% | — | 6 months | 2021-04-09 |
| 4 | Cormorant Asset Management, LP | 77,495,000 HKD | — | 2.22% | — | 6 months | 2021-04-09 |
| 5 | GIC Private Limited | 154,990,000 HKD | — | 4.43% | — | 6 months | 2021-04-09 |
| 6 | Hillhouse Funds | 77,495,000 HKD | — | 2.22% | — | 6 months | 2021-04-09 |
| 7 | Indus Pacific Opportunities Master Fund, Ltd. | 38,747,500 HKD | — | 1.11% | — | 6 months | 2021-04-09 |
| 8 | Invus Public Equities, L.P. | 77,495,000 HKD | — | 2.22% | — | 6 months | 2021-04-09 |
| 9 | Janchor Partners Pan-Asian Master Fund | 232,485,000 HKD | — | 6.65% | — | 6 months | 2021-04-09 |
| 10 | Lake Bleu Prime Healthcare Master Fund Limited | 77,495,000 HKD | — | 2.22% | — | 6 months | 2021-04-09 |
| 11 | Octagon Investments Master Fund LP | 38,747,500 HKD | — | 1.11% | — | 6 months | 2021-04-09 |
| 12 | OrbiMed Funds | 77,495,000 HKD | — | 2.22% | — | 6 months | 2021-04-09 |
| 13 | RA Capital Healthcare Fund, L.P. | 348,727,500 HKD | — | 9.98% | — | 6 months | 2021-04-09 |
| 14 | Rock Springs Capital Master Fund LP | 77,495,000 HKD | — | 2.22% | — | 6 months | 2021-04-09 |
| 15 | Tybourne Equity Master Fund | 38,747,500 HKD | — | 1.11% | — | 6 months | 2021-04-09 |
| 16 | Woodline Master Fund LP | 38,747,500 HKD | — | 1.11% | — | 6 months | 2021-04-09 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 傅唯 | — |
| Company Secretary | 印茵、劉綺華 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 傅唯先生(信託受益人及信託創立人)持有127,645,215股,佔約44.99%;C-Bridge Investment Everest Limited持有50,000,000股,佔約17.62%;C-Bridge IV Investment Two Limited持有38,362,045股,佔約13.52%;C-Bridge Healthcare Fund II, L.P.等受控法團權益持有50,000,000股,佔約17.62%。 |
|---|




